C07K 14/4746
P53
Official title: {p53}
C07K14/4746 (P53) appears on 320 US grants and 412 published applications in this corpus.
Search patents in C07K- Granted patents
- 320
- Published applications
- 412
- Assignees
- 218
- Inventors
- 748
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 7 | 0 |
| 1997 | 12 | 0 |
| 1998 | 21 | 0 |
| 1999 | 19 | 0 |
| 2000 | 12 | 0 |
| 2001 | 18 | 2 |
| 2002 | 9 | 18 |
| 2003 | 10 | 38 |
| 2004 | 14 | 21 |
| 2005 | 7 | 21 |
| 2006 | 13 | 25 |
| 2007 | 14 | 22 |
| 2008 | 10 | 13 |
| 2009 | 9 | 10 |
| 2010 | 8 | 8 |
| 2011 | 12 | 14 |
| 2012 | 1 | 9 |
| 2013 | 6 | 8 |
| 2014 | 5 | 31 |
| 2015 | 12 | 8 |
| 2016 | 7 | 11 |
| 2017 | 7 | 11 |
| 2018 | 9 | 16 |
| 2019 | 10 | 19 |
| 2020 | 11 | 20 |
| 2021 | 13 | 20 |
| 2022 | 13 | 10 |
| 2023 | 6 | 17 |
| 2024 | 7 | 18 |
| 2025 | 10 | 15 |
| 2026 | 3 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Native cell derived vesicles containing tumor suppressor proteins for therapy30 Jun 2026US 12,668,615 B2AnserBio Ltd
- Uses of p53 x-ray co-crystal structures10 Mar 2026US 12,570,645 B2Pmv Pharmaceuticals, Inc.
- Transient inhibition of p53 in gene therapy24 Feb 2026US 12,558,435 B2Fondazione Telethon Ets
- T cell receptors recognizing R175H or Y220C mutation in P5325 Nov 2025US 12,479,902 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Compositions and methods for identification assessment, prevention, and treatment of Ewing sarcoma using TP53 dependency biomarkers and modulators25 Nov 2025US 12,480,163 B2Dana-Farber Cancer Institute, Inc.
- Nonsense mediated decay inhibitor compounds17 Sep 2026US 2026/0272923 A1The Johns Hopkins University
- Recombinant oncolytic adenovirus for cancer therapy20 Aug 2026US 2026/0240928 A1The Johns Hopkins University
- In vivo production of proteins25 Jun 2026US 2026/0174909 A1ModernaTX, Inc.
- Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer19 Feb 2026US 2026/0049111 A1Multivir Inc.
- Method and animal model for inducing bcc tumors5 Feb 2026US 2026/0033466 A1Feldan Bio Inc.
Most cited
By later US patents
- Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays234US 7,410,764 B2The Penn State Research Foundation · 2008
- Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays213US 6,156,504 AThe Penn State Research Foundation · 2000
- Modified polynucleotides for the production of biologics and proteins associated with human disease196US 8,999,380 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides for treating protein deficiency194US 9,061,059 B2Moderna Therapeutics, Inc. · 2015
- Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays144US 7,208,275 B2The Penn State Research Foundation · 2007